Skip to main content
Top

Open Access 01-02-2025 | Chronic Kidney Disease | Article

Birthweight and risk of chronic kidney disease after a type 2 diabetes diagnosis in the DD2 cohort

Authors: Aleksander L. Hansen, Christian F. Christiansen, Charlotte Brøns, Leonie M. Engelhard, Torben Hansen, Jens S. Nielsen, Peter Vestergaard, Kurt Højlund, Niels Jessen, Michael H. Olsen, Henrik T. Sørensen, Peter Rossing, Reimar W. Thomsen, Allan Vaag

Published in: Diabetologia

Login to get access

Abstract

Aims/hypothesis

Low birthweight (LBW) is associated with younger age, less obesity and more hypertension among people recently diagnosed with type 2 diabetes, as well as increased cardiovascular morbidity and mortality risk. It is not known whether LBW is associated with an increased risk of incident chronic kidney disease (CKD) among people with a type 2 diabetes diagnosis.

Methods

Original midwife records were retrieved for 5982 participants with recently diagnosed type 2 diabetes enrolled in the Danish Center for Strategic Research in Type 2 Diabetes (DD2) cohort between 2010 and 2024. They were followed until first incident CKD diagnosis, defined as either two eGFR measurements <60 ml/min per 1.73m2 or two urine albumin/creatinine ratio (UACR) measurements >3 mg/mmol, each 90–365 days apart. Confounder-standardised 10 year risks of CKD were estimated, with death considered as a competing risk. Adjusted hazard ratios (aHRs) for CKD were computed using Cox and spline regression analyses. All analyses were controlled for differences in sex, age at enrolment, calendar year at birth, family history of diabetes and born-at-term status. Mixed-effects models were used to examine the trajectories of eGFR and UACR following enrolment.

Results

A total of 1501 incident CKD endpoints occurred, corresponding to an incidence rate of 42.4 per 1000 person-years over a median follow-up time of 8.3 years. Spline models with birthweight as a continuous measure showed progressively increasing aHRs for CKD with decreasing birthweight. The 10-year standardised risk of CKD was 36.0% in people with LBW (<2500 g) and 30.6% in people with a normal birthweight (2500–4000 g), yielding a risk difference (RD) of 5.5% (95% CI −0.5%, 11.8%) and an aHR of 1.23 (95% CI 0.98, 1.55). People with type 2 diabetes and high birthweight (>4000 g) had a similar 10-year standardised CKD risk compared with normal birthweight (33.1% and 30.6%, respectively). This yielded an RD of 2.5% (95% CI −1.6%, 6.7%) and an aHR of 1.10 (95% CI 0.93, 1.29). In mixed-effects models examining eGFR and UACR trajectories, each 1 kg decrease in birthweight was associated with a 6.6% (95% CI 1.9, 11.1) increase in UACR, whereas no association was found for eGFR.

Conclusions/interpretation

A history of LBW was associated with elevated risk of CKD among people with a recent type 2 diabetes diagnosis, although the precision of risk estimates was limited.

Graphical Abstract

Appendix
Available only for authorised users
Literature
23.
go back to reference Harrell FE (2016) Regression modeling strategies. Springer International Publishing, Cham, Switzerland Harrell FE (2016) Regression modeling strategies. Springer International Publishing, Cham, Switzerland
25.
go back to reference Hernan MA, Robins JM (2023) Causal inference. CRC Press, Boca Raton, FL Hernan MA, Robins JM (2023) Causal inference. CRC Press, Boca Raton, FL
48.
go back to reference Knudsen ST, Mosbech TH, Hansen B, Kønig E, Johnsen PC, Kamper AL (2012) Screening for microalbuminuria in patients with type 2 diabetes is incomplete in general practice. Dan Med J 59(9):A4502PubMed Knudsen ST, Mosbech TH, Hansen B, Kønig E, Johnsen PC, Kamper AL (2012) Screening for microalbuminuria in patients with type 2 diabetes is incomplete in general practice. Dan Med J 59(9):A4502PubMed
Metadata
Title
Birthweight and risk of chronic kidney disease after a type 2 diabetes diagnosis in the DD2 cohort
Authors
Aleksander L. Hansen
Christian F. Christiansen
Charlotte Brøns
Leonie M. Engelhard
Torben Hansen
Jens S. Nielsen
Peter Vestergaard
Kurt Højlund
Niels Jessen
Michael H. Olsen
Henrik T. Sørensen
Peter Rossing
Reimar W. Thomsen
Allan Vaag
Publication date
01-02-2025
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-024-06357-4

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more